ライフサイエンスコーパス: antibody therapy

1 tors, adoptive cell transfer, and bispecific antibody therapy.

2 then FcgammaR activity within the context of antibody therapy.

3 cytic lymphomas, is an attractive target for antibody therapy.

4 immune tolerance mediated by the IL-7Ralpha antibody therapy.

5 activity and a promising target for anti-MIF antibody therapy.

6 ed mice and used it to test human monoclonal antibody therapy.

7 g cells from patients responding to anti-TNF antibody therapy.

8 uggests a possible target for tumor-directed antibody therapy.

9 ure, is a suitable target for neutralization antibody therapy.

10 population for developing neutropenia after antibody therapy.

11 ich are currently inaccessible to monoclonal antibody therapy.

12 mmune response and to synergize with passive antibody therapy.

13 ry abnormalities, which could be targeted by antibody therapy.

14 tive or resistant to Her-2-targeted drugs or antibody therapy.

15 in the spleen was unaffected by OX40 agonist antibody therapy.

16 ols to study STEAP-1 susceptibility to naked antibody therapy.

17 asize to the brain, which is inaccessible to antibody therapy.

18 atory cells had to be blocked with anti-CD25 antibody therapy.

19 s represent potential targets for monoclonal antibody therapy.

20 h rheumatoid arthritis treated with anti-TNF antibody therapy.

21 of recent adverse events with costimulatory antibody therapy.

22 ucidate the mechanism of action of anti-PSCA antibody therapy.

23 but did not affect the outcome of monoclonal antibody therapy.

24 with or after HER-2/neu-specific monoclonal antibody therapy.

25 osis and for selecting tumors for monoclonal antibody therapy.

26 myelotoxicity for non-marrow-targeting (90)Y-antibody therapy.

27 s, even without the routine use of induction antibody therapy.

28 phalitis and have important implications for antibody therapy.

29 aging with (124)I-8H9 followed by (131)I-8H9 antibody therapy.

30 low-grade lymphomas now includes monoclonal antibody therapy.

31 uppression without induction anti-lymphocyte antibody therapy.

32 an be a tumor-specific target for monoclonal antibody therapy.

33 nd six received the E. coli infusion without antibody therapy.

34 e antitumor response to antitumor monoclonal antibody therapy.

35 ection and in those receiving antilymphocyte antibody therapy.

36 xicity associated with conventional anti-CD3 antibody therapy.

37 oth eras were steroid resistant and required antibody therapy.

38 as alternatives to polyclonal or monoclonal antibody therapy.

39 stered once to mice 3 weeks after initiating antibody therapy.

40 tion for treating diseases amenable to local antibody therapy.

41 e antibodies and clinical data of monoclonal antibody therapy.

42 oited for vaccine development and monoclonal antibody therapy.

43 ft survival induced by anti-CD40L monoclonal antibody therapy.

44 nd its implications for vaccine efficacy and antibody therapy.

45 bsequently treated with anti-CD20 monoclonal antibody therapy.

46 epresent particularly attractive targets for antibody therapy.

47 otential for development of a novel class of antibody therapy.

48 act as effector cells within the context of antibody therapy.

49 potentiate the vaccinal effect of antitumor antibody therapy.

50 istance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.

51 rimary and secondary resistance to anti-EGFR antibody therapy.

52 halopathy have occurred following monoclonal antibody therapy.

53 function of monocytes and macrophages during antibody therapy.

54 5% to 44% with the use of anti-IL-2 receptor antibody therapy.

55 dered for testing as adjuvants for antitumor antibody therapy.

56 s that predict lack of response to anti-EGFR antibody therapies.

57 uman or equine immunoglobulins to monoclonal antibody therapies.

58 f a universal flu vaccine and broad-spectrum antibody therapies.

59 esponsiveness to immune checkpoint inhibitor antibody therapies.

60 n identified in the trials of the monoclonal antibody therapies.

61 munological approaches, including monoclonal antibody therapies.

62 gGs could be important for optimal design of antibody therapies.

63 TK11/LKB1-mutated tumors with PD-1-targeting antibody therapies.

64 f HER3 signaling and efficacies of anti-HER3 antibody therapies.

65 he efficacy of current COVID-19 vaccines and antibody therapies(4).

66 After cessation of anti-SR-BI-specific antibody therapy, a rise of the viral load was observed.

67 orine, tacrolimus, and anti-IL-2R monoclonal antibody therapy abrogated the effect of a single-dose p

68 ve immunity while the removal of IL-13 using antibody therapy abrogates this effect.

69 A second cycle of anti-HIV-1 monoclonal antibody therapy, administered to two previously treated

70 proof of concept for future optimization of antibody therapies against encapsulated bacteria.

71 Monoclonal antibody therapy against alpha4beta-integrin is efficaci

72 for the development of vaccines and passive antibody therapy against C. neoformans.

73 rief course of depletive anti-CD4 monoclonal antibody therapy allowed permanent survival of heart, bu

74 The combination antibody therapy allowed safe achievement of an early hi

75 and tacrolimus, without the use of induction antibody therapy, allows withdrawal of prednisone as ear

76 Antibody therapy also reverses the established lesions o

77 at neither allergen challenge nor monoclonal antibody therapy altered circulating Treg frequency.

78 a are needed on cytokine-specific monoclonal antibody therapies and bronchial thermoplasty.

79 nderstand the untoward effects of monoclonal antibody therapies and other immunomodulatory therapies

80 rotein present new challenges for monoclonal antibody therapies and threaten the protective efficacy

81 adnexal MALT lymphoma, especially monoclonal antibody therapy and antibiotic therapy against Chlamydi

82 d an alloantibody response although still on antibody therapy and before the development of a neutral

83 ks mark a new opening in the use of MIPs for antibody therapy and even immunotherapy, as materials of

84 e are promising recent data about anti-HER-2 antibody therapy and other new approaches.

85 ith the emerging role of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and

86 ol group, three patients required monoclonal antibody therapy and two patients required the addition

87 the potential to vastly expand the field of antibody therapy and usher in a new era of cancer vaccin

88 promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of impro

89 ploration of alternative approaches, such as antibody therapy and/or vaccines, for prevention and tre

90 ere rejection (in particular those requiring antibody therapy) and a lower incidence of infection in

91 able on palliative options, bisphosphonates, antibody therapies, and novel targets.

92 plant factors (time to PAK, use of induction antibody therapy, and combinations of immunosuppressive

93 melanomas clinically responding to anti-PD1 antibody therapy, and microsatellite instable colorectal

94 CR2-Fc enhances the therapeutic efficacy of antibody therapy, and the construct may provide particul

95 ease category, previous exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status.

96 was to assess the effects of two monoclonal antibody therapies (anti-OX40L and anti-TSLP) on Treg fr

97 specific adoptive T-cell transfer, agonistic antibody therapy (anti-CD137/4-1BB), and checkpoint bloc

98 (anti-CD137/4-1BB), and checkpoint blockade antibody therapy (anti-PD-L1).

99 and should be considered when no monoclonal antibody therapies are available.

100 s for which neither vaccine nor neutralizing antibody therapies are clinically available.

101 Vaccination and passive antibody therapies are critical for controlling infectio

102 Some antibody therapies are currently being evaluated in clin

103 vaccine is currently available, neutralizing antibody therapies are ineffective, and current antivira

104 ared with traditional small-molecular drugs, antibody therapies are relatively easy to develop; they

105 Phase II trials of radiolabeled antibody therapy are providing promising results.

106 osphonate therapy and rank-ligand monoclonal antibody therapy are the most commonly used agents for m

107 ectal carcinoma should not receive anti-EGFR antibody therapy as part of their treatment.

108 motherapy-based regimens, immune modulators, antibody therapy, as well as cellular therapy.

109 equently occurs in patients after polyclonal antibody therapy (ATGAM or thymoglobulin).

110 concern for the development of vaccines and antibody therapies because the mechanisms that underlie

111 lowed; previous treatment with EGFR-targeted antibody therapy (but not EGFR-targeted tyrosine-kinase

112 transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has differen

113 Nonlytic anti-CD4 monoclonal antibody therapy can be used to induce transplantation t

114 Although antibody therapy can eliminate tumor cells bearing the t

115 using focused ultrasound in combination with antibody therapy can inhibit growth of breast cancer bra

116 ts show that escape viruses from combination antibody therapy cause less severe CHIKV clinical diseas

117 ll death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination

118 cation of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking ant

119 s was most pronounced with WT FR70 and IgG2a antibody therapy compared with the IgG1 chimeric variant

120 Antibody therapy constitutes a major advance in the trea

121 The addition of methylprednisolone to antibody therapy correlated with improved mouse survival

122 Addition of intratumoral CpG to antibody therapy cured large established tumors and prev

123 Antibody therapies currently target only extracellular a

124 Cell and antibody therapies directed against surface molecules on

125 Antibody therapy directed at this target can produce res

126 l fraction of breast cancers, and monoclonal antibody therapy directed toward this antigen is an esta

127 ola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat pat

128 ffects while receiving an anti-PD-1 or PD-L1 antibody therapy either as monotherapy or in combination

129 of 8ANC195 against HIV-1 in vitro and in an antibody therapy experiment in humanized mice.

130 eas for future development in the monoclonal antibody therapy field.

131 useful in the development of next-generation antibody therapies for cancer.

132 ncreased interest in immune-based monoclonal antibody therapies for different malignancies because of

133 Our findings suggest that antibody therapies for infectious diseases that involve

134 s a major challenge for developing effective antibody therapies for neurological diseases.

135 HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.

136 redictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC.

137 rther study of MABp1 anti-interleukin-1alpha antibody therapy for advanced stage cancer is warranted.

138 ols to explore the development of a specific antibody therapy for astrovirus disease.

139 ore the possibility of developing a specific antibody therapy for astrovirus disease.

140 eart the demonstrable efficacy of our unique antibody therapy for elimination of visceral amyloid.

141 ly encourage the investigation of monoclonal antibody therapy for HIV-1 in humans.

142 sponses to increase the clinical benefits of antibody therapy for human cancer.

143 grin alpha(v)beta3 as a molecular target for antibody therapy for Kaposi's sarcoma (KS).

144 Antibody therapy for neutralization of abused drugs has

145 This is the first successful post-exposure antibody therapy for NiV and HeV using a humanized cross

146 ery of chemotherapy and anti-HER2 monoclonal antibody therapy for patients with metastatic, HER2-posi

147 erformance status and previous EGFR-targeted antibody therapy for recurrent or metastatic disease.

148 -NL patients (6.9%) requiring antilymphocyte antibody therapy for rejection than in the CsA-SM-treate

149 of CsA-NL patients requiring antilymphocyte antibody therapy for rejection, fewer International Soci

150 Aerosolized antibody therapy for SARS-CoV-2 could be effective for r

151 ated the development of effective daclizumab antibody therapy for select patients with leukemia/lymph

152 With the exception of monoclonal antibody therapy for the blockade of IgE effector functi

153 support for the development of an anti-CD47 antibody therapy for treatment of human ALL.

154 Addition of anti-IL-2 antibody therapy further improved graft survival, with s

155 ith donor alloantigen combined with anti-CD4 antibody therapy generates CD25+CD4+ T cells that can pr

156 Neutralizing interleukin-4 antibody therapy given only in the newborn period amelio

157 Anti-IL-2 receptor antibody therapy, given intravenously with intervals of

158 However, monoclonal antibody therapy had no additional benefit.

159 However, the development of antibody therapies has focused only on targeting extrace

160 demonstrate that specific depletion of C6 by antibody therapy has a significant effect on guinea pig

161 Anti-CD20 antibody therapy has been a useful medication for managi

162 An ovine polyclonal antibody therapy has been developed against EBOV, named

163 Finally, anti-CD154 antibody therapy has been reported to result in unexpect

164 Indeed, monoclonal antibody therapy has come of age.

165 Monoclonal antibody therapy has emerged as an important therapeutic

166 Although the advent of monoclonal antibody therapy has had a positive effect in the manage

167 To date, pathogen-specific antibody therapy has primarily been developed for both i

168 Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patien

169 Monoclonal antibody therapy has revolutionized cancer treatment by

170 Nerve growth factor (NGF) monoclonal antibody therapy has shown much promise with regard to i

171 Monoclonal antibody therapy has the potential to promote reduced tu

172 Blockbuster antibody therapies have catapulted immune-based approach

173 ntly, immunotherapeutic modalities including antibody therapy have been proposed for the treatment of

174 such as antithymocyte globulin or monoclonal antibody therapy have exhibited hematologic response.

175 Short courses of anti-CD3 monoclonal antibody therapy have provided lasting benefits in recen

176 r-targeted cancer therapies, including armed antibody therapy, have been developed with limited succe

177 n colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequenc

178 b, and anti-epidermal growth factor receptor antibody therapy (if the patient had a RAS wild-type tum

179 In radiolabeled antibody therapy, imaging and biopsy-based methods are u

180 the use of amyloid-beta-directed monoclonal antibody therapies in Alzheimer disease (AD).

181 for targeting interleukin (IL)-17 with novel antibody therapies in the treatment of these diseases.

182 After the failure of antibody therapies in treating hospitalized patients wit

183 approximately 9 d after initiation of IGF-1R antibody therapy in 115 patients with refractory or rela

184 understanding of the mechanism of action of antibody therapy in CLL remains limited.

185 anti-tumor necrosis factor (TNF) monoclonal antibody therapy in Crohn's disease has promoted further

186 -5 (mepolizumab) and anti-CD52 (alemtuzumab) antibody therapy in eosinophilic myeloid diseases has ye

187 e complexes could limit the effectiveness of antibody therapy in humans.

188 The decision to use induction antibody therapy in kidney transplantation is often base

189 95% CI, 0.20 to 2.11) and 62.0% on anti-EGFR-antibody therapy in later lines (odds ratio, 0.09; 95% C

190 validate STEAP-1 as an attractive target for antibody therapy in multiple solid tumors and provide a

191 d by PERCIST 1.0 as early as 9 d into IGF-1R antibody therapy in patients with ESFT can predict the O

192 epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal

193 the mechanisms of action of CD19 monoclonal antibody therapy in pediatric BCP-ALL, we tested an Fc-e

194 tal model suggest the utility of anti-MASP-2 antibody therapy in reperfusion injury and other lectin

195 nstrates the utility of anti-CD14 monoclonal antibody therapy in septic shock and the potential value

196 -to-cell adhesion and has been the target of antibody therapy in several clinical trials.

197 although fewer patients required monoclonal antibody therapy in the cyclosporine group (31% vs. 82%,

198 combining corticosteroid administration with antibody therapy in the mouse model of bubonic plague.

199 vides explanations for the efficacy of IL-2R antibody therapy in uveitis, and suggests that antagonis

200 lovir for the duration of any antilymphocyte antibody therapy, in our kidney and simultaneous pancrea

201 Promising new targets for unconjugated antibody therapy include cellular growth factor receptor

202 Furthermore, IL-7Ralpha antibody therapy increases the frequency of regulatory T

203 Tumor growth resumed on termination of antibody therapy, indicating a cytostatic effect.

204 Combined antibody therapy inhibiting both P-selectin and ICAM-1 v

205 Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesylt

206 Anti-CD47 antibody therapy initiated on larger tumors inhibited tu

207 oute for delivery of both small-molecule and antibody therapies into microscopic, avascular tumors ty

208 Targeted monoclonal antibody therapy is an intriguing new modality for treat

209 Antibody therapy is currently focused on anti-CD20 (ritu

210 example, it is shown that successful passive antibody therapy is dependent on MHC type because of the

211 studies demonstrate that anti-CD8 monoclonal antibody therapy is effective in both the prevention and

212 Antibody therapy is increasingly recognized as a favored

213 Tac in the settings of renal dysfunction or antibody therapy is not a suitable surrogate of activate

214 inistration of HER-2/neu-specific monoclonal antibody therapy is now widely used for the treatment of

215 Of these, antibody therapy is the most amenable to immediate appli

216 B cell-directed monoclonal antibody therapy is the standard of care in KSHV-MCD, an

217 ajor hurdle for the extensive application of antibody therapies lies in the difficulty of generating

218 udies have suggested that several monoclonal antibody therapies lose neutralizing activity against Om

219 Therefore, anti-TNF antibody therapies may increase the risk of serious infe

220 This suggests that anti-OPN antibody therapy may be a potential therapeutic strategy

221 n addition, the therapeutic efficacy of such antibody therapy may be affected by the delivery route u

222 ipients with serum sickness after polyclonal antibody therapy may benefit from TPE by accelerating th

223 Blockade of TNF-alpha bioactivity by antibody therapy may both preserve cardiac function and

224 s indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of prot

225 Anti-B7 antibody therapy may have use as an adjunctive agent for

226 e combination of chemotherapy and monoclonal antibody therapy may improve outcomes for patients with

227 ing data also suggest that longer courses of antibody therapy may improve the duration of response.

228 KCNQ1 antibody therapy may thus present a novel promising ther

229 ravenous immunoglobulin, plasmapheresis, and antibody therapy, newer strategies with more specific ta

230 The role of complement in antibody therapy of cancer is in general poorly understo

231 thod to enhance complement activation during antibody therapy of cancer.

232 ach has potential implications in monoclonal antibody therapy of malignancies beyond the combination

233 P4-mediated antibody therapy offers a unique treatment strategy that

234 on of novel approaches, including monoclonal antibody therapy, offers promise for indolent lymphoma,

235 However, myelotoxicity from (90)Y-antibody therapy often correlates poorly with marrow dos

236 ving epidermal growth factor receptor (EGFR) antibody therapy often experience an acneiform rash of u

237 man-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus lo

238 phenformin enhances the effect of anti-PD-1 antibody therapy on inhibiting tumor growth in the BRAF

239 e effects of chronic neu-specific monoclonal antibody therapy on tumor growth and neu protein express

240 to augment immune responses and dual-purpose antibody therapies or other pharmacological agents that

241 costimulation blockade using CD154-specific antibody therapy or by targeting LFA-1 (also known as CD

242 tional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules,

243 selective depletion of C6 from Lewis rats by antibody therapy prevents hyperacute rejection.

244 Antibody therapies previously approved for inflammatory

245 A 2-week antibody therapy readily cleared HCV RNA from the circul

246 g morphometric analysis of biopsy specimens, antibody therapy reduced the mucosal density of alpha 4

247 IL-7 increases, whereas IL-7Ralpha antibody therapy reduces, the IFN-gamma-producing CD4(+)

248 Monoclonal antibody therapy rendered Fas mutant mice tolerant of mi

249 The use of high-dose 131I antibody therapy requires accurate measurement of normal

250 Furthermore, passive antibody therapy requires continual treatment.

251 OKT3 monoclonal antibody therapy results in an acute clinical syndrome (

252 nded to the addition of anti-CD20 monoclonal antibody therapy (rituximab).

253 r activity of anti-programmed death 1 (PD-1) antibody therapy seen in Hodgkin lymphoma.

254 l carcinoma who are candidates for anti-EGFR antibody therapy should have their tumor tested for KRAS

255 s with mCRC who are candidates for anti-EGFR antibody therapy should have their tumor tested in a Cli

256 Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptom

257 heresis, histone deacetylase inhibitors, and antibody therapies such as alemtuzumab, systemic chemoth

258 g breast cancer often treated with anti-HER2 antibody therapies, such as trastuzumab.

259 pronged tolerogenic mechanisms of IL-7Ralpha antibody therapy suggest a unique disease-modifying appr

260 ical trials have established that monoclonal antibody therapy targeted to PCSK9 may be administered s

261 -associated antigen 4 monoclonal antibodies, antibody therapies targeting prostate-specific membrane

262 g and may explain resistance to antagonistic antibody therapies targeting receptors at the cell surfa

263 for monitoring patients treated with current antibody therapies targeting Region I.

264 The introduction of antibody therapies targeting the Type 2 inflammation pat

265 e feasibility and efficiency of the combined antibody therapy targeting both P-selection and ICAM-1 v

266 nce can be reliably obtained with monoclonal antibody therapy targeting CD45RB.

267 islet allograft acceptance after monoclonal antibody therapy targeting conceptually distinct molecul

268 tial therapeutic targets; indeed, monoclonal antibody therapy targeting IL-20 is effective in the tre

269 Antibody therapy targeting misfolded proteins is a poten

270 uss the use of CD19-specific T cell-engaging antibody therapies (TCEs) as therapeutics for autoimmune

271 d oncology for patients receiving monoclonal antibody therapies that interfere with pretransfusion te

272 recently generated a combination monoclonal antibody therapy that aborted lethal and arthritogenic d

273 These findings suggest that combination of antibody therapy that depletes antigen-expressing normal

274 lope may reflect a characteristic of anti-B1 antibody therapy that is important for its success.

275 Antibody therapies to prevent or limit filovirus infecti

276 possibilities for vaccine design and passive antibody therapies to provide sterilizing immunity and c

277 The use of adjunct antibody therapies to treat infectious diseases shows pr

278 Antibody therapy to inhibit either P-selectin or interce

279 vity and highlights the possibility of using antibody therapy to limit inflammation for other infecti

280 ing soluble form, sIL-6R, can be targeted by antibody therapy to reduce deleterious immune signaling

281 Addition of anti-VEGF antibody therapy to standard chemotherapies has improved

282 g rationale for the development of an IL1RAP antibody therapy to target residual CML stem cells.

283 Advances in vaccination and monoclonal antibody therapies together with integrated surveillance

284 tively) and cell death responses to the HER2 antibody therapy trastuzumab correlated significantly wi

285 When antibody therapy was initiated in overt leukemia, antibo

286 Induction antibody therapy was not routinely used in either group.

287 Antilymphocyte antibody therapy was not used to treat recurrent rejecti

288 nitoring of anti-tumor necrosis factor alpha antibody therapy was performed over 5 days in an additio

289 Using a murine Her2/neu solid tumor model of antibody therapy, we found that Pam2CSK4 significantly e

290 th this, using a murine solid tumor model of antibody therapy, we show that sFlt-1 is involved in res

291 The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice

292 acrophages are potent mediators of antitumor antibody therapy, where they engage target cells via Fcg

293 se II clinical trials combining radiolabeled antibody therapy with 5-FU-based treatments are warrante

294 Combining an unconjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to

295 Dual antibody therapy with bevacizumab and an epidermal growt

296 of real-world patients receiving hepatitis C antibody therapy with LDF/SOF +/- RBV support the prescr

297 alpha (IL10Ralpha) and CD20, the target for antibody therapy with Rituxan.

298 a (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemo

299 cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab.

300 treatment refractory CD requiring monoclonal antibody therapy with ustekinumab.